The company is a women's health diagnostics company that uses proprietary proteomics and bioinformatics platforms to discover, develop, and commercialize blood-based biomarker tests for maternal and neonatal health. Its lead product, the PreTRM test, is a non-invasive blood test that predicts preterm birth risk during pregnancy and has demonstrated clinical benefits including reduced neonatal complications and hospital costs. The company generates revenue through reimbursement from health insurance payers, integrated healthcare systems, and employers, leveraging proprietary biobanks of pregnant women's specimens and machine learning capabilities to develop an expanding pipeline of diagnostic tests for other pregnancy complications including preeclampsia, gestational diabetes, and fetal growth restriction.